ImmunoGen starts clinical testing with its EGFR-targeting ADC, IMGN289 for several types of cancers

ImmunoGen, Inc.Nov 6 2013

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its ADC technology, today announced the start of clinical testing with its EGFR-targeting ADC, IMGN289.

"There is a lot of excitement around IMGN289," commented Dr. Charles Morris, EVP and Chief Development Officer. "It is an antibody-drug conjugate, or ADC, to a well-known target, EGFR, and a potential new treatment for several types of cancers - including squamous cell lung and head and neck cancers - that have very limited treatment options today. We are delighted to now be gaining clinical experience with this promising new agent."